News & Events - MitoRx

- In The Media
- Posted 8 July, 2026
MitoRx adds Babraham in Cambridge to its Oxford obesity drug capability – Business Weekly
Read More
- In The Media
- Posted 22 June, 2026
Companies to Watch 2026: Seven innovators shaping next-generation obesity therapies – Clarivate
Read More
- In The Media
- Posted 11 June, 2026
MTRX-31 restores mitochondrial metabolism in obesity – BioWorld
Read More
- In The Media
- Posted 11 June, 2026
MitoRx’s new obesity drug targets metabolism, not appetite – Longevity Technology
Read More
- Press Release
- Posted 9 June, 2026
MitoRx Therapeutics Strengthens Leadership Team with C-Suite and Board Appointments to Support Next Phase of Growth
Read More
- Press Release
- Posted 8 June, 2026
MitoRx Therapeutics presents promising preclinical data on MTRX31, a mitochondrial-targeted small molecule for metabolically unhealthy obesity, at the American Diabetes Association’s 2026 Scientific Sessions
Read More
- Event
Sachs 2nd Annual Obesity and Cardiometabolic Innovation Forum, June 5
Read More
- Event
American Diabetes Association Scientific Sessions 2026, June 5-8
Read More
- Publication
- Posted 1 June, 2026
Myo-004 (MTRX31) induces bodyweight loss in DIO at thermoneutrality by switching metabolism from fat to carbohydrate oxidation
Read More
- Event
European Association for the Study of Diabetes (EASD), 28 September – 2 October
Read More